Parexel Launches FSP Integrated Solutions to Move Beyond Headcount-Based CRO Outsourcing With AI-Enabled Outcomes Model

• Parexel, a leading global CRO and clinical development partner, has announced the transformation of its functional service provider services into a new strategic business model — Parexel FSP Integrated Solutions — pairing its 8,000+ FSP resources across clinical, data management, biometrics, regulatory, and safety with ParexelAI-enabled technology under a single point of accountability, led by newly appointed President Sanjay Vyas.

• The new model is explicitly designed to move the FSP CRO market away from headcount-based outsourcing toward outcomes-driven, technology-enabled capacity that scales flexibly with sponsor pipeline demands — addressing growing sponsor pressure to improve R&D productivity, reduce handoffs, and access specialized expertise across increasingly complex global development programs.

Parexel, a leading global CRO and clinical development partner, announced on September 23, 2026, from Raleigh, North Carolina, the transformation of its functional service provider services into Parexel FSP Integrated Solutions — a new strategic business model that integrates specialist global talent, ParexelAI-enabled technology, and operational expertise into a single, coordinated delivery structure under one point of accountability. To lead the transformation, Parexel has created a new executive role — President, Integrated Solutions, Clinical Logistics and Managing Director India — appointing Sanjay Vyas to unify FSP offerings across all functions and deliver a more consistent, technology-driven sponsor experience.

The model is structured around four operational principles for sponsors: the ability to build flexible global operating models aligned to long-term business objectives; the capacity to scale up or down as pipeline demands shift, with faster access to global infrastructure and specialist talent; the application of ParexelAI capabilities to automate manual work, streamline workflows, and improve speed and efficiency; and access to a full breadth of FSP functional capabilities — spanning clinical, data management, biometrics, regulatory, and safety — through more than 8,000 dedicated FSP resources worldwide. Parexel positions the model as an enterprise capability partner rather than a staff augmentation service, with custom solutions configured to the scope and duration each individual program requires.

The announcement signals a deliberate positioning shift in how Parexel is framing its FSP CRO offering. Headcount-based outsourcing — in which sponsors pay for bodies deployed against work — has been the dominant FSP model for decades. Parexel FSP Integrated Solutions is explicitly positioned against this model: the emphasis is on outcomes, accountability, and technology-enabled delivery rather than resource volume. For CRO sponsors navigating the dual pressure of rising development complexity and intensifying R&D productivity expectations, the shift reflects a structural change in what sponsors are demanding from FSP partners — fewer handoffs, clearer ownership, and integrated technology that reduces manual work rather than simply providing additional labor capacity.

FSP Integrated Solutions builds on Parexel’s ongoing investment in ParexelAI, the company’s suite of AI capabilities embedded across its broader clinical development operations. Within the FSP context, ParexelAI is deployed to automate high-volume manual processes, improve workflow efficiency, and surface insights that enable faster, more confident sponsor decision-making — extending the value of FSP engagement beyond human expertise into an integrated technology layer. Parexel’s global delivery infrastructure, spanning more than 22,000 employees across 40+ years of clinical development experience, provides the therapeutic depth and regulatory expertise underpinning the FSP Integrated Solutions model.

“Biopharmaceutical companies are facing unprecedented pressure to improve R&D productivity and enhance post-approval product lifecycle activities while navigating increasingly complex development programs, especially as the industry moves away from headcount-based outsourcing. Customers need partners that take greater accountability for outcomes and can deliver the flexible capacity, functional expertise, AI-enabled technology and scale required to evolve alongside their business.”

Rob Goodwin, Chief Operating Officer, Parexel